20,275 Shares in Fresenius Medical Care AG & Co. KGaA $FMS Acquired by Sequoia Financial Advisors LLC

Posted by Brian Himes on Jul 22nd, 2026

Sequoia Financial Advisors LLC acquired a new stake in shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,275 shares of the company’s stock, valued at approximately $457,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FMS. CIBC Private Wealth Group LLC boosted its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock valued at $36,000 after purchasing an additional 1,103 shares in the last quarter. Arax Advisory Partners raised its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 121.6% during the 4th quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after buying an additional 885 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Fresenius Medical Care AG & Co. KGaA during the 4th quarter worth $58,000. Finally, Group One Trading LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA in the third quarter valued at about $74,000. 8.37% of the stock is currently owned by institutional investors.

Fresenius Medical Care AG & Co. KGaA Trading Up 2.5%

Shares of FMS stock opened at $24.68 on Wednesday. The firm has a market capitalization of $13.25 billion, a P/E ratio of 12.99, a P/E/G ratio of 4.34 and a beta of 0.78. Fresenius Medical Care AG & Co. KGaA has a twelve month low of $20.02 and a twelve month high of $27.64. The company has a quick ratio of 0.86, a current ratio of 1.20 and a debt-to-equity ratio of 0.40. The stock’s fifty day simple moving average is $22.83 and its 200 day simple moving average is $22.86.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $1.05 earnings per share (EPS) for the quarter. The business had revenue of $5.34 billion during the quarter. Fresenius Medical Care AG & Co. KGaA had a return on equity of 8.90% and a net margin of 4.88%. As a group, sell-side analysts predict that Fresenius Medical Care AG & Co. KGaA will post 2.24 EPS for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA Increases Dividend

The company also recently disclosed an annual dividend, which was paid on Monday, June 8th. Stockholders of record on Friday, May 22nd were paid a $0.8716 dividend. This is an increase from Fresenius Medical Care AG & Co. KGaA’s previous annual dividend of $0.79. This represents a dividend yield of 402.0%. The ex-dividend date of this dividend was Friday, May 22nd. Fresenius Medical Care AG & Co. KGaA’s payout ratio is currently 32.11%.

Analyst Ratings Changes

FMS has been the topic of a number of recent analyst reports. Sanford C. Bernstein started coverage on Fresenius Medical Care AG & Co. KGaA in a research report on Thursday, July 16th. They issued a “market perform” rating on the stock. Jefferies Financial Group raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a report on Friday, May 8th. Citigroup restated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Friday. Morgan Stanley reaffirmed an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Wednesday, May 6th. Finally, Weiss Ratings cut shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, May 7th. Six equities research analysts have rated the stock with a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat, Fresenius Medical Care AG & Co. KGaA has a consensus rating of “Reduce” and an average price target of $28.00.

View Our Latest Research Report on Fresenius Medical Care AG & Co. KGaA

About Fresenius Medical Care AG & Co. KGaA

(Free Report)

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.